![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Abstract
Purpose. To study the interaction between radiation dose distribution and hypofractionated radiotherapy with respect to the risk of radiation pneumonitis (RP) estimated from normal tissue complication probability (NTCP) models. Material and methods. Eighteen non-small cell lung cancer patients previously treated with helical tomotherapy were selected. For each patient a 3D-conformal plan (3D-CRT) plan was produced in addition to the delivered plan. The standard fractionation schedule was set to 60 Gy in 30 fractions. Iso-efficacy comparisons with hypofractionation were performed by changing the fractionation and the physical prescription dose while keeping the equivalent tumor dose in 2 Gy fractions constant. The risk of developing RP after radiotherapy was estimated using the Mean Equivalent Lung Dose in 2-Gy fractions (MELD2) NTCP model with α/β=4 Gy for the residual lung. Overall treatment time was kept constant. Results. The mean risk of clinical RP after standard fractionation was 7.6% for Tomotherapy (range: 2.8–15.9%) and 9.2% for 3D-CRT (range 3.2–20.2%). Changing to 20 fractions, the Tomotherapy plans became slightly less toxic if the tumor α/β ratio, (α/β)T, was 7 Gy (mean RP risk 7.5%, range 2.8–16%) while the 3D-CRT plans became marginally more toxic (mean RP risk 9.8%, range 3.2–21%). If (α/β)T was 13 Gy, the mean estimated risk of RP is 7.9% for Tomotherapy (range: 2.8–17%) and 10% for 3D-CRT (range 3.2–22%). Conclusion. Modern highly conformal dose distributions are radiobiologically more forgiving with respect to hypofractionation, even for a normal tissue endpoint where α/β is lower than for the tumor in question.
Acknowledgements
ISV is supported by The Lundbeck Foundation Center for Interventional Research in Radiation Oncology (CIRRO) and The Danish Council for Strategic Research. SMB acknowledges support from the National Cancer Institute grant no. 2P30 CA 014520-34.
Declaration of interest: The authors report no conflicts of interest. The authors alone are responsible for the content and writing of the paper.